Introduction
Caseous lymphadenitis (CLA) caused by Corynebacterium pseudotuberculosis is a chronic disease of sheep and goats. Two forms of the disease have been described, an external form (abscesses in superficial lymph nodes and subcutaneous tissues) and an internal form (abscesses located internally in organs and lymph nodes, especially the lungs, liver, kidneys, and mediastinal, bronchial and lumbar lymph nodes). Each form of the disease can cause major economic losses because infected sheep have to be culled from breeding flocks due to poor physical condition or decreased fertility, and carcasses or parts of carcasses are condemned at abattoirs (6) .
Although several bacterial species have been isolated from CLA lesions in sheep, C. pseudotuberculosis has been implicated as the major pathogen in this condition (11, 19) . C. pseudotuberculosis is a Gram-positive facultative intracellular bacterial rod that produces a phospholipase D (PLD) exotoxin. Both PLD and bacterial cell wall have been determined as possible virulence factors of C. pseudotuberculosis (5, 22) .
Once established, CLA is difficult to eradicate. Chemotherapy is futile, because C. pseudotuberculosis are protected by a thick capsule that surrounds the abscesses (5, 6) . Prevention of CLA has been limited to good herd management programmes that reduce opportunities for infection of wounds and cull infected animals from the herd. However, these methods have had limited effectiveness. Because of the difficulty in controlling the disease, there has been much investigation into the mechanisms of protective immunity that would help in the development of a successful vaccine (5, 6, 18) . To immunise against CLA, different vaccines have been developed. These vaccines contain whole cells (WC) (3, 4) , cell walls (CW) (4) or toxoid (6, 9) of C. pseudotuberculosis, or there are combined clostridialcorynebacterial vaccines (9) . Several adjuvants (such as, Freund's incomplete adjuvant (6) , muramyl dipeptide (3), aluminium salt-based adjuvant (13) have also been used to enhance immunogenicity with variable success. Although large decreases in prevalence of CLA could be achieved by about 70% of sheep producers by either using a different vaccine or making adjustments to their vaccination programs (17) , insufficient data are available to evaluate the protection of the vaccines prepared from local strains of C. pseudotuberculosis against bacterial challenge. The purpose of this pilot study was to identify major antigens of C. pseudotuberculosis isolated from different sheep flocks in Turkey and to evaluate the efficacy of the vaccine formulated as bacterin + toxoid + Freund's complete adjuvant (FCA) against bacterial challenge in lambs.
Material and Method
Sample collection and isolation: In order to isolate vaccine strains of C. pseudotuberculosis, 65 sheep were selected from 6 different flocks (Ceylanpınar, Gözlü, Polatlı, Tahirova and Altınova Agricultural Administrations Directory and a public farm near Ankara) comprising in total about 20.000 sheep. Clinical inspection of the animals revealed that these 65 sheep had abscessed external lymph nodes (mandibular, superficial cervical, subiliac, lateral retropharyngeal and parotid). The clinical inspection was confirmed at the necropsy of 27 affected animals, when typical abscesses were found. A total of 65 swabs were taken carefully under sterile conditions from abscessed external lymph nodes of the sheep and placed in Stuart's transport medium (Difco Laboratories, Detroit, MI, USA). In addition, abscessed mediastinal and bronchial lymph nodes were taken from the 27 necropsied sheep and placed in physiological saline solution (PSS) (pH. 7.2) with 50% glycerine for transport to the laboratory. Swabs and lymph node samples were inoculated onto brain-heart infusion agar (BHIA) (Oxoid, CM375, Basingstoke, UK) supplemented with 7% sheep blood. These BHIA plates were incubated in 5-7% CO 2 atmosphere aerobically for 7 days at 37 °C. Isolates were identified as C. pseudotuberculosis by use of previously described methods (5, 11, 15) .
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE):
Of the 36 C. pseudotuberculosis strains that were isolated in this study, 14 strains were preferred for SDS-PAGE analysis due to their high haemolytic titre (HT) of exotoxins (7) with sheep red blood cells (RBC). To identify potential vaccine strains of C. pseudotuberculosis, these 14 strains were analysed by SDS-PAGE.
Briefly, C. pseudotuberculosis strains were grown in 80 ml brain heart infusion broth (BHIB) (Oxoid, CM225) containing 0.05% Tween 80 incubated at 37 °C with a magnetic shaker for 48 h. Cultures were stored at 4°C for 12 h and then centrifuged at 5.000 rpm for 20 min. Supernatant was discarded and pellets were washed 3 times with sterile distilled water. Washed cell pellets were suspended in phosphate buffer solution (PBS) (pH. 7.2) and pulse-sonicated (Sonic 300, Artek Systems, Farmingdale, NY, USA) 3 times for 10 min on ice. Whole cell lysates were exposed to diethylether (Merck, 926.5000, KgaA 64271, Darmstadt, Germany) for 6 h and centrifuged at 6.000 rpm for 30 min. Supernatants were collected and stored -20 °C until used (16) .
SDS-PAGE was carried out by the method of Laemmli (14) using a 15% separating gel and a 4% stacking gel. Protein bands were stained with Coomassie blue. Samples were applied to a Vertical Slab Gel Unit (Hoefer Scientific Instruments, San Francisco, CA, USA). Cluster analysis of the similarity values was performed by the UPGMA algorithm, using the Cluster IC programme (25) .
Detection of vaccine strains: C. pseudotuberculosis Pl 18 and C. pseudotuberculosis Cy 5 strains were identified as vaccine strains according to the results of SDS-PAGE and high HT of exotoxins.
Preparation of vaccines: C. pseudotuberculosis Pl 18 and Cy 5 strains were grown in BHIA supplemented with 7% fetal bovine serum (Sigma, B2771, St. Louis, MO, USA) incubated in microaerobic atmosphere at 37 °C for 48 h. A single colony was removed from the BHIA, placed in 250 ml of BHIB including 0.1% Tween 80 and incubated at 37 °C with shaking for 72 h. The cultures were allowed to settle at 4 °C for 12 h and were then centrifuged at 4°C for 20 min at 6.000 rpm. Supernatants were removed and were filtered through 0.45 µm and 0.22 µm filters (Sartorius), respectively. Merthiolate (Lilly, USA) was added to supernatants to a final concentration of 1/10.000 and they were incubated at 4 °C for 12 h. The HT value of the exotoxins was determined as 1/32 for C. pseudotuberculosis Pl 18 strain and 1/16 for C. pseudotuberculosis Cy 5 strain. Formaldehyde (Sigma, F1635) was added to toxins to a final concentration of 0.6% and they were incubated at 4°C for 7 days. The toxins were then checked for sterility in BHIA and used as toxoid in the vaccine. Pellets were washed three times with PBS (pH. 7.2) and centrifuged at 4.500 rpm for 30 min (4 °C). Thereafter, the pellets were prepared in PBS and 10-fold dilutions were made. From these dilutions, 0.1 ml suspension was inoculated onto duplicate plates of BHIA and incubated at 37 °C for 48 h and colonies were enumerated. The number of microorganisms was estimated spectrophotometrically at 530 nm and the concentration of bacterins was adjusted by PBS to 1.5x10 8 cfu/ml of C. pseudotuberculosis Pl 18
and Cy 5 strains. Formaldehyde was added to bacterins to a final concentration of 0.6% and they were incubated at 4 °C for 7 days. The bacterins were then checked for sterility and used in the vaccine (13 Haemolysis inhibition test (HIT): HIT was carried out as described previously (7). Controls included sheep RBC (no exotoxin) and diluted exotoxin (no serum). The titers 1/8 and higher ones were evaluated as positive in the test.
Vaccination and challenge of lambs: In total, 112 lambs were found to be negative for antibodies against the exotoxin of C. pseudotuberculosis as determined by the HIT. Of these 112 lambs, 90 lambs were allotted at random to 3 groups (30 lambs in each group). Group 1 was vaccinated with a vaccine prepared from C. pseudotuberculosis Pl 18 strain; Group 2 with a vaccine prepared from C. pseudotuberculosis Cy 5 strain; and Group 3 was used as a control and was subcutaneously injected with 2 ml PBS. Each lamb in Groups 1 and 2 received two 0.5 ml doses of the vaccine. The vaccine was administered by sc injection in the left axillar region and interval between doses was 4 weeks. For the determination of the vaccine efficacy, four weeks after the second vaccination, the lambs in all groups were challenged intradermally in the right prescapulary lymph node region with 2 ml of a 24 h broth culture of live C. pseudotuberculosis Pl 18 strain (6x10 6 cfu/ml) (21) .
Clinical observation of lambs and bacterial examinations:
Lambs were monitored clinically throughout the 7 weeks after the challenge. In week 7, 8 lambs from each group were randomly selected, necropsied and abscessed lymph nodes were counted (1) and cultured for bacterial examinations.
Statistical analysis: Statistical analysis was performed using SPSS (V.11.0) package program. Comparisons of the results were examined by the chi-square test (30).
Results

Isolation:
In total 36 (39.1%) C. pseudotuberculosis strains were isolated, of which 27 (29.3%) originated from external lymph nodes and 9 (9.7%) from lungs or associated lymph nodes. Smears of colonies revealed Gram-positive coryneform microorganisms. The isolates were identified as C. pseudotuberculosis on the basis of motility, catalase, urease, nitrate, methyl red and fermentation of glucose, xylose, mannitol, lactose, sucrose, trehalose, salicin, inositol, maltose, galactose and arabinose.
SDS-PAGE: SDS-PAGE revealed more than 21 bands ranging in size from 15 kDa to 194 kDa present in different concentrations in isolates as determined by visual assessment of their approximate molecular masses. The 15, 25.7, 31.2, 36, 43, 66.5, 80 and 194 kDa bands were consistently recognised and 25.7, 43 and 80 kDa were determined as major bands in 14 C. pseudotuberculosis strains. Bands of each strain were compared with protein profiles of other strains and their similarity rate was determined. When the similarity coefficiencies of 14 strains were evaluated, two subgroups were seen to have formed. The first group included C. pseudotuberculosis Pl 18 strain and contained 8 strains that were identical (similarity coefficient 71-100), while the second group included C. pseudotuberculosis Cy 5 strain and contained 6 strains that were identical (similarity coefficient 71-100).
Clinical, necropsy and bacteriological findings in lambs: External lymph nodes were enlarged in 5, 9 and 24 lambs after challenge with C. pseudotuberculosis Pl 18 strain in Groups 1-3, respectively. The internal form of CLA was observed in 2, 2 and 8 of the 8 lambs necropsied in Groups 1-3 respectively. C. pseudotuberculosis was isolated from 2/8 necropsied lambs in Group 1, 3/8 lambs in Group 2 and 7/8 lambs in Group 3 (Table 1) . Using the ki-square test, the proportion of vaccinated lambs (Groups 1 and 2) that developed CLA lesions and the isolation ratio of C. pseudotuberculosis were significantly less (p<0.001) than in the control lambs. 
Discussion and Conclusion
CLA has been reported in many countries worldwide (5) . In sheep, it has serious economic consequences, especially in the USA and Australia (20) . The disease has long been known in Turkey (12) , but recently the prevalence of CLA has accelerated in Turkish sheep breeding, especially in large sheep flocks (11) . Although several bacterial organisms have been isolated from CLA lesions, C. pseudotuberculosis has been implicated as the major pathogen in this condition (19) . In the present study, a total of 36 (39.1 %) C. pseudotuberculosis strains were isolated from sheep materials. Other microorganisms isolated from cultures of the materials included Micrococcus spp., Staphylococcus aureus, Streptococcus epidermidis and Pseudomonas aeruginosa.
To develop an effective vaccine for CLA it is necessary to target major determinant antigens of C. pseudotuberculosis. The exotoxin PLD and bacterial cell wall lipids have been identified as virulence factors of the organism. Brown and colleagues (6) reported that the presence of anti-exotoxin antibodies in the initial bacterial multiplication period may limit local spread and general dissemination of C. pseudotuberculosis. Some variation in the ability of the different strains of C. pseudotuberculosis to produce exotoxins, their ability to kill white mice and their haemolytic activity were detected. A highly significant relationship between the number of mice dying and the haemolytic activity has been demonstrated (23) . The SDS-PAGE technique has been successfully employed to characterise protein antigens of C. pseudotuberculosis (2, 10, 16 ). Muckle and co-workers (16) showed that antibodies to at least seven antigens of a WC lysate of C. pseudotuberculosis were present in the serum of naturally infected sheep and goats. Three antigens of about 31.5, 68 and 120 kDa in size were consistently recognised by all infected animal sera. In this study, analyses of proteins of C. pseudotuberculosis strains revealed more than 21 bands in gel and the 80, 43 and 25.7 kDa bands were detected as major protein antigens. The C. pseudotuberculosis Pl 18 and Cy 5 strains were preferred as vaccine strains due to their high HT and due to them being representative of their groups in SDS-PAGE analyses.
Colostrum-deprived lambs vaccinated by im with 10 mg (dry weight) of C. pseudotuberculosis WC or CW and immunity-challenged by iv injection of 3.1x10 4 cfu of C. pseudotuberculosis were significantly protected from CLA, as demonstrated by fewer abscesses and organisms in the lungs of lambs vaccinated with WC or CW than in control lambs (4) . In ten male 9-week-old goats vaccinated via sc with formalized exotoxin containing Freund's incomplete adjuvant, at necropsy, 5 of the 10 vaccinated goats did not have lesions of CLA, 3 had abscesses limited to the inoculation site and 2 had disseminated bacterial lesions. Of the 5 non-vaccinated controls, 4 had disseminated abscesses and 1 had a single abscess in an internal node (6). Piontkowski and Shivvers, (18) reported that vaccination with commercial vaccine (Caseous D-T, Colorado Serum Co. Denver, USA) including C. pseudotuberculosis bacterin + toxoid protected sheep against challenge by exposure to live C. pseudotuberculosis (1.95x10 5 cfu/ml) in sc injection. In this study, the isolation ratio of C. pseudotuberculosis and symptoms of CLA after challenge in Groups 1 and 2 were lower than in the control group (Table 1) .
Although the lambs and their mothers had not been previously vaccinated against CLA, out of the 140 lambs, 28 lambs were found to be positive by HIT in this research. This could be attributed to 28 lamb sera giving false positive results due to cross-reaction with other bacteria (8) .
Effective vaccination against CLA may require stimulation of the host reticuloendothelial system with an accompanying adjuvant (3, 23) . In the present study, FCA was preferred for vaccination in lambs because insufficient date are available to evaluate its adjuvant activity in sheep. Significant injection site reactions were not observed in experimental lambs compared with control lambs throughout the study. The potency of FCA allows lower doses of bacterin + toxoid vaccine, thus reducing the incidence of site reactions.
Several vaccine trials have been performed using different combination of vaccines in sheep (4, 13, 18) but, absolute protective immunity was not established. This could attribute that the C. pesudotuberculosis is a facultative intracellular parasite, thus development both humoral immunity and cell-mediated immunity.
CLA is characterised by abscessed external and internal lymph nodes (1, 6) . In this study, there were significantly fewer abscesses and fewer organisms, especially in Group 1 than in the control group (p<0.001). Although absolute immunity was not established in Groups 1 and 2, the vaccine contained a local C. pseudotuberculosis (Pl 18) strain and formulated as per ml of the vaccine 1.5x10 8 cfu of C. pseudotuberculosis bacterin + toxoid + 1/2 FCA of the toxoid, we obtained encouraging results regarding the potential of this vaccine to control of CLA in sheep.
